Hepatitis C Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Hepatitis C Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global Hepatitis C Therapeutics market. The report provides comprehensive information on Hepatitis C Therapeutics, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global Hepatitis C Therapeutics market. It analyses the treatment usage patterns in the global Hepatitis C Therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global Hepatitis C Therapeutics sector. It quantifies the unmet need in the global Hepatitis C Therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

    The scope of the report includes:

• An overview of Hepatitis C Therapeutics which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized global Hepatitis C Therapeutics market revenue, annual cost of therapy and treatment usage patterns data (from 2001 to 20010, forecast for 10 years to 2020.
• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
• Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
• Competitor assessment including drug launch analysis and drug sales forecasts.
• Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
• Analysis of unmet need in the market and target product profile including opportunity for target product.
• Technology trends analytic framework to assess strength of pipeline.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends.
• Clinical trials mapping of trials for Hepatitis C Therapeutics in different regions.
• An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
• Analysis of the current and future market competition in the global Hepatitis C Therapeutics market. Company profiles including business description, financial overview and SWOT analysis.
• Analysis of licensing agreements during 2004-2010 in the Hepatitis C Therapeutics market. M&A analysis which includes M&A deals by size and geography.
• Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
• Direct quotes from key opinion leaders (KOL) or physicians in the Hepatitis C Therapeutics market.

Reasons to Buy

• The report will enhance your decision making capability. It will allow you to: Develop business strategies and perform superior market quantification analysis by Understanding the trends shaping and driving the global Hepatitis C Therapeutics market. Understanding treatment preferences of physicians in disease state and across treatment flow. Accessing market sizing, forecasts and quantified growth opportunities in the global Hepatitis C Therapeutics market till 2020. Quantifying patient population in the global Hepatitis C Therapeutics market to better design product pricing & launch plans. Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by performing benchmarking analysis and growth opportunities against currently marketed products Identifying market entry points based on safety, efficacy, and pricing parameters. Assessing competitiveness of products in market by understanding the strength and weakness of current competition. Develop and design your in-licensing and out-licensing strategies by Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products. Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products. Track drug sales in the global Hepatitis C Therapeutics market from 2001 to 2020 Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships. What’s the next big thing in the global Hepatitis C Therapeutics market landscape? Identify, understand and capitalize

Table of Contents

1 Executive Summary

2 Disease Overview
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.5 Diagnosis
2.6 Pathology
2.6.1 Grading
2.7 Treatment
2.7.1 Treatment Guidelines
2.7.2 Treatment Providers

3 Market Characterization
3.1 Global
3.1.1 Market Size
3.1.2 Forecasts
3.2 Geographical Split
3.2.1 Overview
3.3 The US
3.3.1 Market Size
3.3.2 Drivers & Barriers
3.3.3 Impact on the Market
3.3.4 Forecasts
3.3.5 Future Impact
3.3.6 Drug Sales Forecast
3.3.7 Pricing & Reimbursement Scenario
3.4 The UK
3.4.1 Market Size
3.4.2 Drivers & Barriers
3.4.3 Impact on the Market
3.4.4 Forecasts
3.4.5 Future Impact
3.4.6 Drug Sales Forecast
Pricing & Reimbursement Scenario
3.5 Germany
3.5.1 Market Size
3.5.2 Drivers & Barriers
3.5.3 Impact on the Market
3.5.4 Forecasts
3.5.5 Future Impact
3.5.6 Drug Sales Forecast
3.5.7 Pricing & Reimbursement Scenario
3.6 France
3.6.1 Market Size
3.6.2 Drivers & Barriers
3.6.3 Impact on the Market
3.6.4 Forecasts
3.6.5 Future Impact
3.6.6 Drug Sales Forecast
3.6.7 Pricing & Reimbursement Scenario
3.7 Italy
3.7.1 Market Size
3.7.2 Drivers & Barriers
3.7.3 Impact on the Market
3.7.4 Forecasts
3.7.5 Future Impact
3.7.6 Drug Sales Forecast
3.7.7 Pricing & Reimbursement Scenario
3.8 Spain
3.8.1 Market Size
3.8.2 Drivers & Barriers
3.8.3 Impact on the Market
3.8.4 Forecasts
3.8.5 Future Impact
3.8.6 Drug Sales Forecast
3.8.7 Pricing & Reimbursement Scenario
3.9 Japan
3.9.1 Market Size
3.9.2 Drivers & Barriers
3.9.3 Impact on the Market
3.9.4 Forecasts
3.9.5 Future Impact
3.9.6 Drug Sales Forecast
3.9.7 Pricing & Reimbursement Scenario
3.1 Brazil
3.10.1 Market Size
3.10.2 Drivers & Barriers
3.10.3 Impact on the Market
3.10.4 Forecasts
3.10.5 Future Impact
3.10.6 Drug Sales Forecast
3.11 India
3.11.1 Market Size
3.11.2 Drivers & Barriers
3.11.3 Impact on the Market
3.11.4 Forecasts
3.11.5 Future Impact
3.11.6 Drug Sales Forecast
3.12 China
3.12.1 Market Size
3.12.2 Drivers & Barriers
3.12.3 Impact on the Market
3.12.4 Forecasts
3.12.5 Future Impact
3.12.6 Drug Sales Forecast
3.13 Russia
3.13.1 Market Size
3.13.2 Drivers & Barriers
3.13.3 Impact on the Market
3.13.4 Forecasts
3.13.5 Future Impact
3.13.6 Drug Sales Forecast

4 Drivers and Barriers
4.1 Opportunity & Unmet Need Analysis
4.2 Key Takeaway
4.3 Competitive Assessment
4.4 Overview
4.5 Strategic Competitor Assessment
4.6 Marketed Product Profiles
4.7 Marketed Drug 1
4.8 Overview
4.9 Efficacy

5 Safety
5.1 Clinical Study Details
5.2 Annual Cost of Therapy

6 Pipeline Assessment
6.1 Overview
6.2 Strategic Pipeline Assessment
6.3 Pipeline Analysis by Phase of Development
6.3.1 Phase III Clinical Pipeline
6.3.2 Phase II Clinical Pipeline
6.3.3 Phase I Clinical Pipeline
6.3.4 Pre-clinical & Discovery Phase
6.4 Pipeline by Mechanism of Action
6.5 Technology Trends Analytical Framework
6.6 Clinical Pipeline by Mechanism of Action, and by Monotherapy & Combination therapy
6.7 Most Promising Drugs under Clinical Development
6.8 Most Promising Drug Profiles

7.3.1 Overview
7.3.2 Efficacy
7.3.3 Safety

8 Partners in Development
8.1 Licensing Agreements by Phase of Development
8.2 Licensing Agreements by Deal Size
8.3 Licensing Agreements by Territory

9 Clinical Trials Mapping
9.1 Clinical Trials by Region/Country
9.2 Clinical Trials by Phase
9.3 Clinical Trials by Trial Status
9.4 Prominent Sponsors
9.5 Top Ten Companies Participating in Therapeutics Clinical Trials

10 Strategic Assessment
10.1 Key Events Impacting the Future Market
10.2 Future Market Competition Scenario

11 Strategic Assessment

12 Key Events Impacting the Future Market
12.1 Market Impact Analysis

13 Future Market Scenario
13.1 Future Players in the Market

14 Company Profiles
14.1 Company A
14.1.1 Business Description
14.1.2 Financial Overview
14.1.3 SWOT Analysis
14.2 Company B
14.2.1 Business Description
14.2.2 Financial Overview
14.2.3 SWOT Analysis
14.3 Company C
14.3.1 Business Description
14.3.2 Financial Overview
14.3.3 SWOT Analysis
14.4 Company D
14.4.1 Business Description
14.4.2 Financial Overview
14.4.3 SWOT Analysis
14.5 Company E
14.5.1 Business Description
14.5.2 Financial Overview
14.5.3 SWOT Analysis
14.6 Company F
14.6.1 Business Description
14.6.2 Financial Overview
14.6.3 SWOT Analysis
14.7 Company G
14.7.1 Business Description
14.7.2 Financial Overview
14.7.3 SWOT Analysis

15 M&A Analysis
15.1 Key Highlights
15.2 Key Deals’ Analysis
15.3 M&A Deals by Geography
15.4 Licensing Deals by Phase
15.5 M&A Deals by Deal Size

16 Expert Opinion

17 Appendix